Gastrointestinal Cancer clinical trials at UCSD
3 in progress, 1 open to eligible people
BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
open to eligible people ages 18 years and up
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: - Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab - Learn more about the side effects of BT5528 - Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. - Learn more about BT5528 therapy alone and in combination with nivolumab.
La Jolla, California and other locations
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
Sorry, not yet accepting patients
The purpose of this study is to determine if it is possible to make and safely administer a 'personalized' cancer vaccine for people diagnosed with an upper gastrointestinal tract cancer.
La Jolla, California
Prevention of Colorectal Cancer Through Multiomics Blood Testing
Sorry, in progress, not accepting new patients
The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.
San Diego, California and other locations
Our lead scientists for Gastrointestinal Cancer research studies include Ezra Cohen, MD Shumei Kato, MD.
Last updated: